U.S. Markets closed

Introducing Acer Therapeutics (NASDAQ:ACER), A Stock That Climbed 27% In The Last Year

Simply Wall St

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boost your returns by picking above-average stocks. For example, the Acer Therapeutics Inc. (NASDAQ:ACER) share price is up 27% in the last year, clearly besting than the market return of around 9.0% (not including dividends). So that should have shareholders smiling. We'll need to follow Acer Therapeutics for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long.

See our latest analysis for Acer Therapeutics

Acer Therapeutics didn't have any revenue in the last year, so it's fair to say it doesn't yet have a proven product (or at least not one people are paying for). So it seems that the investors more focused on would could be, than paying attention to the current revenues (or lack thereof). It seems likely some shareholders believe that Acer Therapeutics will significantly advance the business plan before too long.

As a general rule, if a company doesn't have much revenue, and it loses money, then it is a high risk investment. The is usually a significant chance that they will need more money for business development, putting them at the mercy of capital markets. So the share price itself impacts the value of the shares (as it determines the cost of capital). While some companies like this go on to deliver on their plan, making good money for shareholders, many end in painful losses and eventual de-listing.

Acer Therapeutics had net cash of US$36m when it last reported (December 2018). That's not too bad but management may have to think about raising capital or taking on debt, unless the company is close to breaking even. Given the share price has increased by a solid 27% in the last year, its fair to say investors remain excited about the future, despite the potential need for cash. The image below shows how Acer Therapeutics's balance sheet has changed over time; if you want to see the precise values, simply click on the image.

NasdaqCM:ACER Historical Debt, April 5th 2019

Of course, the truth is that it is hard to value companies without much revenue or profit. However you can take a look at whether insiders have been buying up shares. It's often positive if so, assuming the buying is sustained and meaningful. Luckily we are in a position to provide you with this free chart of insider buying (and selling).

A Different Perspective

Acer Therapeutics boasts a total shareholder return of 27% for the last year. A substantial portion of that gain has come in the last three months, with the stock up 12% in that time. This suggests the company is continuing to win over new investors. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.